Welcome to our dedicated page for JNCE news (Ticker: JNCE), a resource for investors and traders seeking the latest updates and insights on JNCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JNCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JNCE's position in the market.
Jounce Therapeutics, Inc. (Nasdaq: JNCE) has appointed Jigar Raythatha, former CEO of Constellation Pharmaceuticals, to its board of directors. Raythatha brings over 20 years of biotech experience, including his role as chief business officer at Jounce. His insights are expected to enhance the company's strategic direction amid ongoing development in cancer immunotherapy. Additionally, founding board member Cary Pfeffer will resign effective December 31, 2021, after significant contributions since 2013. This leadership transition aims to strengthen Jounce's ongoing growth and innovation in the immuno-oncology space.
Jounce Therapeutics (NASDAQ: JNCE), a clinical-stage immunotherapy company, announced participation in multiple investor conferences this September. Key events include the Wells Fargo Virtual Healthcare Conference on September 10, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, Baird's Global Healthcare Conference on September 15, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29. Live webcasts will be available on Jounce's website, with replays archived for 30 days post-presentation.
Jounce Therapeutics (NASDAQ: JNCE) reported financial results for Q2 2021, announcing the completion of monotherapy dose escalation enrollment for JTX-8064 with a selected target dose of 700 mg. The company ended the quarter with $246.1 million in cash and equivalents, bolstered by a $25 million milestone payment from Gilead. License and collaboration revenue reached $25.4 million, up from zero in 2020. The net loss shrank to $4 million from $28 million year-over-year. Jounce plans to begin indication-specific expansions in Q3 2021.
Jounce Therapeutics (NASDAQ: JNCE) announced it will report its second quarter 2021 financial results and provide a corporate update on August 5, 2021, before market open. Management will host a live conference call at 8:00 AM ET to discuss the results. The company focuses on developing cancer immunotherapies and biomarkers, with multiple programs including JTX-8064 and vopratelimab currently in clinical trials. Jounce is committed to enabling the immune system to combat tumors, further advancing its innovative pipeline.
Jounce Therapeutics (NASDAQ: JNCE) announced that its Chief Scientific Officer, Dmitri Wiederschain, will participate in a panel at the William Blair’s Biotech Focus Conference on July 14, 2021, at 4:20 PM ET. The event will be held virtually, and a webcast of the discussion will be accessible via Jounce's website, with a replay available for 30 days post-event. Jounce specializes in developing cancer immunotherapies and has multiple ongoing clinical trials, including its key programs JTX-8064 and vopratelimab.
Jounce Therapeutics (NASDAQ: JNCE) provided an update on its clinical and discovery pipeline during its 2021 R&D Day. Notable advancements include the INNATE trial of JTX-8064, with expansion cohorts expected to begin enrollment in Q3 2021. The company introduced two new LILRB family targets, LILRB1 and LILRB4, enhancing its immunotherapy portfolio. Key presentations highlighted targeting myeloid cells in cancer treatment and the development of biomarker-enabled therapies aimed at improving patient responsiveness to existing treatments.
Jounce Therapeutics (NASDAQ: JNCE) has announced a virtual R&D Day scheduled for June 23, 2021, from 10:00 a.m. to 12:00 p.m. ET. The event will include presentations from Jounce management and scientific team members, featuring key opinion leader Robert Schreiber, PhD. Attendees can access the webcast through the Investors and Media section of Jounce's website. The company focuses on developing novel cancer immunotherapies and currently has multiple programs, including the promising JTX-8064 and vopratelimab, aimed at enhancing the immune response against tumors.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced FDA clearance for its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, which triggers a $25 million milestone payment from Gilead Sciences, Inc. GTX-1811 aims to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells and will be developed by Gilead under the name GS-1811. Jounce is eligible for up to $660 million in additional milestone payments and royalties based on sales, affirming its commitment to advancing cancer immunotherapy.
Jounce Therapeutics (NASDAQ: JNCE) will have its CEO Richard Murray participate in a fireside chat at the Raymond James Human Health Innovation Conference on June 21, 2021, at 12:40 p.m. ET. This virtual event will be accessible via the company's website, where a replay will be available for 30 days. Jounce is focused on developing innovative cancer immunotherapies, including its lead programs JTX-8064 and vopratelimab, aimed at reprogramming tumor-associated macrophages and activating T cells, respectively.
Jounce Therapeutics (NASDAQ: JNCE) presented updates on the INNATE and SELECT clinical trials at the ASCO Virtual Annual Meeting. The Phase 1 INNATE trial is evaluating JTX-8064, a monoclonal antibody, as both a monotherapy and in combination with pimivalimab across various advanced solid tumors. Jounce announced plans for expansion cohorts based on translational data, aiming for proof-of-concept in multiple cancer types. The SELECT trial is assessing pimivalimab in biomarker-selected non-small cell lung cancer patients, with expected data reports in 2022. Both trials are on track according to projections.
